Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tuberous Sclerosis × Propranolol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Hemangioma 3 Sarcoma, Kaposi 2 Sarcoma 2 Multiple Myeloma 2 Melanoma 2 Hemangiosarcoma 2 Hemangioma, Cavernous, Central Nervous System 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Stomach Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Kidney Neoplasms 1 Histiocytoma, Malignant Fibrous 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Sirolimus 6 Everolimus 4 ganaxolone 1 dactolisib 1 Vigabatrin 1 Propranolol 1 Aspirin 1 Anticonvulsants 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02104011 2018-01-23

STBETA

University Hospital, Bordeaux

Phase 2 Completed

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡